Live Breaking News & Updates on Edalliance Received Coronary In Stent Restenosis Isr Ide Approval October 2022 And De Novo Artery Lesions On January 6th 2023 This Will Complement The Substantial Experience That Company Has Gained With Selution Denovo Trial Europe Medalliance 39s Unique Deb Technology Involves Microreservoirs Which Containa Mixture Of Biodegradable Polymer Intermixed Anti Restenotic Drug Sirolimus Applied Asa Coating Surface An Angioplasty Balloon These Provide Controlled Sustained Release For Up To 90 Days Proprietary Cat Cell Adherent Enables Be Coated Onto Balloons Efficiently Transferred Adhere Vessel Lumen When Delivered Via Expansion Slr Is Commercially Available

Geneva [Switzerland], March 15 (ANI/PRNewswire): MedAlliance has announced enrollment of over 1,000 patients in its ground-breaking SELUTION DeNovo coronary randomized study. Recruitment is now a third of the way towards the target of 3,326 patients. SELUTION DeNovo compares the treatment strategy using a novel sirolimus drug-eluting balloon [DEB SELUTION], versus a limus drug-eluting stent [DES]. SELUTION DeNovo is the largest DEB study ever initiated, involving up to 70 participating sites across 15 countries. Patients are randomized before any vessel preparation to reflect current medical practice and to reduce bias. The objectives of the study are to demonstrate non-inferiority at both one and five years, and superiority for target vessel failure (TVF) at five years. This study is designed to change medical practice, as the majority of de novo coronary lesions are currently treated with a permanent metallic stent. SELUTION SLR consists of an angioplasty balloon coated with MicroRes ....

France General , Switzerland General , United States , Richard Kenyon , Georges Pompidou , Christian Spaulding , Cardiology Department , Cell Adherent Technology , Paris Cite University , European Hospital Georges Pompidou , Assistance Publique Hopitaux De Paris , Medalliance Chairman , Middle East , Geneva Switzerland , Arch 15 Ani Prnewswire Medalliance Has Announced Enrollment Of Over 1 , 000 Patients In Its Ground Breaking Selution Denovo Coronary Randomized Study Recruitment Is Nowa Third Of The Way Towards Target 3 , 326 Patients Selution Denovo Compares The Treatment Strategy Usinga Novel Sirolimus Drug Eluting Balloon Deb , Ersusa Limus Drug Eluting Stent Des Selution Denovo Is The Largest Deb Study Ever Initiated , Nvolving Up To 70 Participating Sites Across 15 Countries Patients Are Randomized Before Any Vessel Preparation Reflect Current Medical Practice And Reduce Bias The Objectives Of Study Demonstrate Non Inferiority At Both One Five Years , Nd Superiority For Target Vessel Failure Tvf At Five Years This Study Is Designed To Change Medical Practice , S The Majority Of De Novo Coronary Lesions Are Currently Treated Witha Permanent Metallic Stent Selution Slr Consists An Angioplasty Balloon Coated With Microreservoirs Containinga Mixture Biodegradable Polymer And Anti Restenotic Drug Sirolimus These Provide Controlled Sustained Release For Over 90 Days , Imilar Toa Des , Ut Without Leaving Behinda Metal Scaffold , Hich Has Been Associated Witha Complication Rate Of 2 Annually Quot This Isa Major Milestone For The Selution Denovo Trial , S It Is Now The Largest Deb Study Ever Conducted , Uot Said Co Principal Investigator Professor Christian Spaulding ,